Study summary · research use only
Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This rat study examined the effect of the peptide vilon (Lys-Glu) on urinary bladder tumors induced by the carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine. Tumors developed in 56% of vilon-treated animals versus 75.5% of controls. The authors report vilon produced a 2-fold decrease in the incidence of preneoplastic and early neoplastic changes in the bladder mucosa and was associated with inhibited carcinogenesis in this model. Species: rats.
Abstract
The effect of peptide vilon (Lys-Glu) on urinary bladder carcinogenesis in rats was studied. Urinary bladder tumors were induced with a selective carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine. The tumors developed in 56% vilon-treated animals and in 75.5% controls. Vilon 2-fold decreased the incidence of preneoplastic and early neoplastic changes in urinary bladder mucosa and significantly inhibited carcinogenesis.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.